1
|
Benitha G, Ramani P, Jayakumar S, Ramalingam K. Molecular expression of Forkhead Box C2 gene (FOXC2) and Prospero homeobox gene (PROX-1) in oral squamous carcinoma and their correlation with clinicopathological parameters: A prospective cohort study. J Oral Maxillofac Pathol 2024; 28:216-225. [PMID: 39157851 PMCID: PMC11329087 DOI: 10.4103/jomfp.jomfp_394_23] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/03/2023] [Revised: 02/05/2024] [Accepted: 03/29/2024] [Indexed: 08/20/2024] Open
Abstract
Background Forkhead box C2 gene (FOXC2) acts as an epithelial-mesenchymal transition (EMT) inducer while Prospero homeobox 1 gene (PROX-1) function as a regulator of lymphangiogenesis and angiogenesis in oral squamous cell carcinoma (OSCC). It is presumed that PROX-1 has both tumour-suppressive and oncogenic effects. The main aim of this study is to evaluate the role of PROX-1 and FOXC2 in the invasion and progression of OSCC cases and to correlate their expression with various histopathological parameters. Materials and Methods A prospective cohort study was conducted in a total sample size of 52 OSCC tissues and histologically tumour-free margins of 20. mRNA expression and protein levels of FOXC2 and PROX-1 were evaluated using real-time PCR and sandwich enzyme-linked immunosorbent assay techniques. Chi-square analysis and correlation analysis were done. Kaplan-Meier analysis evaluated the survival rate. Results Mean Ct values of FOXC2 were 1.915 ± 0.519 and PROX-1 was 0.061 ± 0.173. There was a significant 2-fold increase in the FOXC2 expression and a 0.5-fold decrease in the PROX-1 expression in OSCC tissue. Increased levels of FOXC2 protein and decreased levels of PROX-1 with a mean difference of 1.64 ± 0.73 ng/ml and 1.27 ± 0.33 ng/ml were observed in OSCC compared to histologically tumour-free margins. A significant positive correlation was found between the FOXC2 expression and clinicopathological parameters such as staging, perineural invasion (PNI) and lymphovascular invasion (LVI) whereas PROX-1 showed a significant negative correlation with histopathological parameters such as staging, PNI, LVI and tumour staging. There was a significant positive correlation between the PROX-1 and histologically tumour-free margins in disease-free survival patients (P-value = 0.03). Conclusion FOXC2 and PROX-1 expressions were correlated with lymphovascular invasion, OSCC tumour staging and PNI. Thus, FOXC2 and PROX-1 could be possible therapeutic targets in the treatment of OSCC that can inhibit the EMT in OSCC and thereby favouring a better prognosis.
Collapse
Affiliation(s)
- Georgia Benitha
- Department of Oral and Maxillofacial Pathology, Saveetha Dental College and Hospitals, Saveetha Institute of Medical and Technical Sciences, Saveetha University, Chennai, Tamil Nadu, India
| | - Pratibha Ramani
- Department of Oral and Maxillofacial Pathology, Saveetha Dental College and Hospitals, Saveetha Institute of Medical and Technical Sciences, Saveetha University, Chennai, Tamil Nadu, India
| | - Selvaraj Jayakumar
- Department of Biochemistry, Saveetha Dental College and Hospitals, Saveetha Institute of Medical and Technical Sciences, Saveetha University, Chennai, Tamil Nadu, India
| | - Karthikeyan Ramalingam
- Department of Oral and Maxillofacial Pathology, Saveetha Dental College and Hospitals, Saveetha Institute of Medical and Technical Sciences, Saveetha University, Chennai, Tamil Nadu, India
| |
Collapse
|
2
|
Kwon S, Ban K, Hong YK, Sung JS, Choi I. PROX1, a Key Mediator of the Anti-Proliferative Effect of Rapamycin on Hepatocellular Carcinoma Cells. Cells 2022; 11:cells11030446. [PMID: 35159256 PMCID: PMC8834064 DOI: 10.3390/cells11030446] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/21/2021] [Revised: 01/21/2022] [Accepted: 01/25/2022] [Indexed: 02/04/2023] Open
Abstract
The MTOR signal is known to be activated in various cancer cells including hepatocellular carcinoma (HCC) cells. Rapamycin, a specific inhibitor of MTOR, has been widely used as an immunosuppressant in organ transplant patients, and its clinical application has been recently expanded to cancer therapy. In this study, the anti-proliferative effect of rapamycin was investigated in four different HCC cell lines. Rapamycin effectively inhibited the proliferation of Huh7 or Hep3B, but not that of HepG2 or SNU3160 cells. Interestingly, rapamycin increased Prospero-related homeobox 1 (PROX1) expression at the protein level, but did not affect its transcript in Huh7 as well as Hep3B cells. Moreover, immunoprecipitation assays showed that PROX1 ubiquitination was downregulated by rapamycin. Furthermore, PROX1 over-expression or siRNA knock-down in Huh7 and Hep3B cells reduced or increased proliferation, respectively. The effect of PROX1 over-expression on the sensitivity to rapamycin was not synergistic, but the effect of MTOR inhibition on cell proliferation was diminished by PROX1 siRNA. Finally, Huh7 cells were inoculated into the flanks of nude mice and rapamycin was injected daily for 14 days. The xenograft volume was decreased and PROX1 expression was increased by rapamycin. These results indicate that PROX1 plays a key role in the anti-proliferative effect of rapamycin and suggest that the increased PROX1 by MTOR inhibition can be used as a useful marker for predicting whether HCC cells can be affected by rapamycin.
Collapse
Affiliation(s)
- Sora Kwon
- Department of Pharmaceutical Engineering, Hoseo University, Asan 31499, Korea;
| | - Kiwon Ban
- Department of Biomedical Sciences, City University of Hong Kong, Hong Kong 999077, China;
| | - Young-Kwon Hong
- Department of Surgery, Norris Comprehensive Cancer Center, Keck School of Medicine, University of Soutern California, Los Angeles, CA 90033, USA;
| | - Jung-Suk Sung
- Department of Life Science, Dongguk University, Goyang 10326, Korea;
| | - Inho Choi
- Department of Pharmaceutical Engineering, Hoseo University, Asan 31499, Korea;
- Correspondence:
| |
Collapse
|
3
|
Lendvai G, Szekerczés T, Illyés I, Csengeri M, Schlachter K, Szabó E, Lotz G, Kiss A, Borka K, Schaff Z. Autophagy activity in cholangiocarcinoma is associated with anatomical localization of the tumor. PLoS One 2021; 16:e0253065. [PMID: 34129628 PMCID: PMC8205141 DOI: 10.1371/journal.pone.0253065] [Citation(s) in RCA: 6] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/02/2020] [Accepted: 05/27/2021] [Indexed: 12/14/2022] Open
Abstract
The presence of autophagy has been indicated in cholangiocarcinoma (CC), which disease has poor prognosis and limited treatment options. Recently, CC has been classified by anatomical localization as intrahepatic (iCC), perihilar (pCC) and distal (dCC), showing different clinical and molecular characteristics. Thus, our aim was to compare autophagy activity in CC samples resected from different anatomical locations. Further, we investigated whether autophagy could be modulated in cell lines originated from iCC and extrahepatic CC (eCC) following the treatments with autophagy inhibitory and inducing agents. Tissue microarrays were prepared from 70 CC (28 iCC, 19 pCC and 23 dCC), 31 adjacent non-tumorous and 9 hepatocellular carcinoma (HCC) samples. Autophagy markers LC3, p62 and Beclin1 as well as proliferation marker Ki-67 were monitored by immunohistochemistry and were associated with patients' survival. Modulation of autophagy was investigated in cell lines originated from iCC (HuH-28), eCC (TFK-1) and HCC (HepG2) by treating the cells with chloroquine (CQ) for inhibition and with Rapamycin, 5-Fluorouracil (5-FU) and Sorafenib for induction of autophagy. Our results indicated an inhibited autophagy in iCC and pCC tumor tissues, whereas active autophagy seemed to occur in dCC, especially in samples displaying low Ki-67 index. Additionally, low level of Beclin1 and high level of Ki-67 were associated with poor overall survival in dCC, suggesting the prognostic role of these proteins in dCC. Beside a baseline autophagy detected in each cell line, Rapamycin and 5-FU induced autophagy in iCC and HepG2 cell lines, Sorafenib in iCC cells. A chemotherapy agent in combination with CQ decreased IC50 effectively in the cell lines where basal and/or induced autophagy were present. In conclusion, we revealed differences in the autophagy activities of CC tissues and cell lines originated from different anatomical locations, which might influence patients' treatment. Our results also suggest a prognostic role of Beclin1 and Ki-67 in dCC.
Collapse
Affiliation(s)
- Gábor Lendvai
- 2nd Department of Pathology, Semmelweis University, Budapest, Hungary
| | - Tímea Szekerczés
- 2nd Department of Pathology, Semmelweis University, Budapest, Hungary
| | - Ildikó Illyés
- 2nd Department of Pathology, Semmelweis University, Budapest, Hungary
| | - Milán Csengeri
- 2nd Department of Pathology, Semmelweis University, Budapest, Hungary
| | - Krisztina Schlachter
- Department of Surgical and Molecular Pathology, Center of Tumor Pathology, National Institute of Oncology, Budpest, Hungary
| | - Erzsébet Szabó
- 2nd Department of Pathology, Semmelweis University, Budapest, Hungary
| | - Gábor Lotz
- 2nd Department of Pathology, Semmelweis University, Budapest, Hungary
| | - András Kiss
- 2nd Department of Pathology, Semmelweis University, Budapest, Hungary
| | - Katalin Borka
- 2nd Department of Pathology, Semmelweis University, Budapest, Hungary
| | - Zsuzsa Schaff
- 2nd Department of Pathology, Semmelweis University, Budapest, Hungary
| |
Collapse
|
4
|
Li M, Deng Y, Zhuo M, Zhou H, Kong X, Xia X, Su Z, Chen Q, Guo P, Mo P, Yu C, Li W. Demethylase-independent function of JMJD2D as a novel antagonist of p53 to promote Liver Cancer initiation and progression. Am J Cancer Res 2020; 10:8863-8879. [PMID: 32754284 PMCID: PMC7392006 DOI: 10.7150/thno.45581] [Citation(s) in RCA: 20] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/03/2020] [Accepted: 06/28/2020] [Indexed: 12/13/2022] Open
Abstract
Background: As a histone demethylase, JMJD2D can enhance gene expression by specifically demethylating H3K9me2/3 and plays an important role in promoting colorectal cancer progression. However, its role in liver cancer remains unclear. Methods: The expression of JMJD2D was examined in human liver cancer specimens and non-tumorous liver tissues by immunohistochemical or immunoblot analysis. JMJD2D expression was knocked down in liver cancer cells using small hairpin RNAs, and cells were analyzed with Western blot, real-time PCR, cell viability, colony formation, and flow cytometry assays. Cells were also grown as tumor xenografts in nude mice, and the tumor cell proliferation and apoptosis were measured by immunohistochemical analysis. The relationship between JMJD2D and p53 was studied by co-immunoprecipitation, chromatin immunoprecipitation, and electric mobility shift assay. Wild-type and JMJD2D-knockout mice were intraperitoneally injected with diethylnitrosamine (DEN) to induce liver tumors and the liver cancer initiation and progression were investigated. Results: JMJD2D was frequently upregulated in human liver cancer specimens compared with non-tumorous liver tissues. The overall survival of liver cancer patients with high JMJD2D expression was significantly decreased compared to that with low JMJD2D expression. JMJD2D knockdown reduced liver cancer cell proliferation and xenograft tumor growth, sensitized cells to chemotherapeutic drug-induced apoptosis, and increased the expression of cell cycle inhibitor p21 and pro-apoptosis gene PUMA. Genetically, JMJD2D deficiency protected mice against DEN-induced liver cancer initiation and progression. Knockout of tumor suppressor p53 significantly reduced the effects of JMJD2D knockdown on cell proliferation, apoptosis, and the expression of p21 and PUMA, suggesting that JMJD2D regulates liver cancer cell functions in part through inhibiting p53 signaling pathway. Mechanistically, JMJD2D directly interacted with p53 and inhibited p53 recruitment to the p21 and PUMA promoters in a demethylation activity-independent manner, implicating a demethylase-independent function of JMJD2D as a novel p53 antagonist. In addition, JMJD2D could activate Wnt/β-catenin signaling to promote liver cancer cell proliferation. Conclusion: Our study demonstrates that JMJD2D can antagonize the tumor suppressor p53 and activate an oncogenic signaling pathway (such as Wnt/β-catenin signaling pathway) simultaneously to promote liver cancer initiation and progression, suggesting that JMJD2D may serve as a novel target for liver cancer treatment.
Collapse
|
5
|
Old wine in new bottles: Drug repurposing in oncology. Eur J Pharmacol 2020; 866:172784. [DOI: 10.1016/j.ejphar.2019.172784] [Citation(s) in RCA: 44] [Impact Index Per Article: 11.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/10/2019] [Revised: 11/05/2019] [Accepted: 11/07/2019] [Indexed: 02/07/2023]
|
6
|
Liu G, Ma X, Wang Z, Wakae K, Yuan Y, He Z, Yoshiyama H, Iizasa H, Zhang H, Matsuda M, Sugiyama R, Yuan Z, Muramatsu M, Li L. Adenosine deaminase acting on RNA-1 (ADAR1) inhibits hepatitis B virus (HBV) replication by enhancing microRNA-122 processing. J Biol Chem 2019; 294:14043-14054. [PMID: 31366735 DOI: 10.1074/jbc.ra119.007970] [Citation(s) in RCA: 12] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/14/2019] [Revised: 07/04/2019] [Indexed: 12/18/2022] Open
Abstract
Adenosine deaminases acting on RNA-1 (ADAR1) involves adenosine to inosine RNA editing and microRNA processing. ADAR1 is known to be involved in the replication of various viruses, including hepatitis C and D. However, the role of ADAR1 in hepatitis B virus (HBV) infection has not yet been elucidated. Here, for the first time, we demonstrated ADAR1 antiviral activity against HBV. ADAR1 has two splicing isoforms in human hepatocytes: constitutive p110 protein and interferon-α (IFN-α)-responsive p150 protein. We found that overexpression of ADAR1 decreased HBV RNA in an HBV culture model. A catalytic-site mutant ADAR1 also decreased HBV RNA levels, whereas another adenosine deaminases that act on the RNA (ADAR) family protein, ADAR2, did not. Moreover, the induction of ADAR1 by stimulation with IFN-α also reduced HBV RNA levels. Decreases in endogenous ADAR1 expression by knock-down or knock-out increased HBV RNA levels. A major hepatocyte-specific microRNA, miRNA-122, was found to be positively correlated with ADAR1 expression, and exogenous miRNA-122 decreased both HBV RNA and DNA, whereas, conversely, transfection with a miRNA-122 inhibitor increased them. The reduction of HBV RNA by ADAR1 expression was abrogated by p53 knock-down, suggesting the involvement of p53 in the ADAR1-mediated reduction of HBV RNA. This study demonstrated, for the first time, that ADAR1 plays an antiviral role against HBV infection by increasing the level of miRNA-122 in hepatocytes.
Collapse
Affiliation(s)
- Guangyan Liu
- College of Basic Medical Sciences, Shenyang Medical College, Shenyang 110034, China.,Institute of Human Virology, Key Laboratory of Tropical Disease Control of Ministry of Education, Zhongshan School of Medicine, Sun Yat-sen University, Guangzhou 510080, Guangdong, China.,Department of Molecular Genetics, Kanazawa University, Graduate School of Medical Science, 13-1 Takara-machi, Kanazawa 920-8640, Japan
| | - Xiancai Ma
- Institute of Human Virology, Key Laboratory of Tropical Disease Control of Ministry of Education, Zhongshan School of Medicine, Sun Yat-sen University, Guangzhou 510080, Guangdong, China
| | - Zhe Wang
- Department of Molecular Genetics, Kanazawa University, Graduate School of Medical Science, 13-1 Takara-machi, Kanazawa 920-8640, Japan.,Department of Medical Oncology, Affiliated Zhongshan Hospital of Dalian University, Dalian 116001, China.,The Key Laboratory of Biomarker High Throughput Screening and Target Translation of Breast and Gastrointestinal Tumor, Dalian University, Dalian 116001, China
| | - Kousho Wakae
- Department of Molecular Genetics, Kanazawa University, Graduate School of Medical Science, 13-1 Takara-machi, Kanazawa 920-8640, Japan
| | - Yaochang Yuan
- Institute of Human Virology, Key Laboratory of Tropical Disease Control of Ministry of Education, Zhongshan School of Medicine, Sun Yat-sen University, Guangzhou 510080, Guangdong, China
| | - Zhangping He
- Institute of Human Virology, Key Laboratory of Tropical Disease Control of Ministry of Education, Zhongshan School of Medicine, Sun Yat-sen University, Guangzhou 510080, Guangdong, China
| | - Hironori Yoshiyama
- Department of Microbiology, Faculty of Medicine, Shimane University, 89-1 Enya, Izumo, Shimane 693-8501, Japan
| | - Hisashi Iizasa
- Department of Microbiology, Faculty of Medicine, Shimane University, 89-1 Enya, Izumo, Shimane 693-8501, Japan
| | - Hui Zhang
- Institute of Human Virology, Key Laboratory of Tropical Disease Control of Ministry of Education, Zhongshan School of Medicine, Sun Yat-sen University, Guangzhou 510080, Guangdong, China
| | - Mami Matsuda
- Department of Virology II, National Institute of Infectious Disease, Tokyo 164-8640, Japan
| | - Ryuichi Sugiyama
- Department of Virology II, National Institute of Infectious Disease, Tokyo 164-8640, Japan
| | - Zhiyu Yuan
- College of Basic Medical Sciences, Shenyang Medical College, Shenyang 110034, China
| | - Masamichi Muramatsu
- Department of Molecular Genetics, Kanazawa University, Graduate School of Medical Science, 13-1 Takara-machi, Kanazawa 920-8640, Japan .,Department of Virology II, National Institute of Infectious Disease, Tokyo 164-8640, Japan
| | - Linghua Li
- Department of Infectious Diseases, Guangzhou Eighth People's Hospital, Guangzhou Medical University, Guangzhou 510060, China
| |
Collapse
|
7
|
Abstract
Liver transplantation is the definitive treatment for patients with end-stage liver disease. Liver transplantation is also the optimal treatment for patients with hepatocellular carcinoma (HCC), especially in the setting of chronic liver disease. Unfortunately, due to the worldwide shortage of organs, this treatment is not available for all patients with HCC. Strict selection criteria have been developed in order to obtain optimal results. A surgical perspective of the preoperative selection, perioperative management, and postoperative care of patients is reviewed in depth and provides an overview for obtaining optimal long-term results from liver transplantation for HCC. With rigorous selection and patient management, excellent long-term outcomes can be obtained with liver transplantation for patients with HCC.
Collapse
|
8
|
Huang CH, Lei KF, Tsang NM. Apoptosis and cell cycle arrest of hepatocellular carcinoma spheroids treated by an alternating electric field. Biotechnol Prog 2019; 35:e2787. [DOI: 10.1002/btpr.2787] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/25/2018] [Revised: 12/17/2018] [Accepted: 02/05/2019] [Indexed: 12/22/2022]
Affiliation(s)
- Chun-Hao Huang
- Program in Biomedical Engineering; College of Engineering, Chang Gung University; Taoyuan Taiwan
| | - Kin Fong Lei
- Graduate Institute of Biomedical Engineering, Chang Gung University; Taoyuan Taiwan
- Department of Radiation Oncology; Chang Gung Memorial Hospital; Linkou Taiwan
| | - Ngan-Ming Tsang
- Department of Radiation Oncology; Chang Gung Memorial Hospital; Linkou Taiwan
- Department of Traditional Chinese Medicine; Chang Gung University; Taoyuan Taiwan
| |
Collapse
|
9
|
Jeon JS, Kwon S, Ban K, Kwon Hong Y, Ahn C, Sung JS, Choi I. Regulation of the Intracellular ROS Level Is Critical for the Antiproliferative Effect of Quercetin in the Hepatocellular Carcinoma Cell Line HepG2. Nutr Cancer 2019; 71:861-869. [PMID: 30661409 DOI: 10.1080/01635581.2018.1559929] [Citation(s) in RCA: 12] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/21/2022]
Abstract
Quercetin, an antioxidant flavonoid, has been known that it can induce the cell cycle arrest and apoptosis of hepatocellular carcinoma (HCC) cells by the stabilization or induction of p53. Here, we found that quercetin reduced the proliferation of HepG2 cells significantly, but not Huh7 cells. Interestingly, quercetin down-regulated the intracellular ROS level in HepG2 cells, but not Huh7 cells. Functional study using siRNA showed that the proliferation of HepG2 cells was still regulated by quercetin in the absence of p53. Furthermore, we confirmed the effect of quercetin on HepG2 cells by H2O2 supplementation. This study demonstrates that the antiproliferative effect of quercetin on HCC cells can be mediated by reducing intracellular ROS, which is independent of p53 expression.
Collapse
Affiliation(s)
- Ji-Sook Jeon
- a Department of Pharmaceutical Engineering , Hoseo University , Asan , Republic of Korea
| | - Sora Kwon
- a Department of Pharmaceutical Engineering , Hoseo University , Asan , Republic of Korea
| | - Kiwon Ban
- b Department of Biomedical Sciences , City University of Hong Kong , Kowloon Tong , Hong Kong
| | - Young- Kwon Hong
- c Department of Surgery , Norris Comprehensive Cancer Center, Keck School of Medicine, University of Southern California , Los Angeles , CA , USA
| | - Curie Ahn
- d Department of Internal Medicine , Seoul National University College of Medicine , Seoul , Republic of Korea
| | - Jung-Suk Sung
- e Department of Life Science , Dongguk University , Goyang , Republic of Korea
| | - Inho Choi
- a Department of Pharmaceutical Engineering , Hoseo University , Asan , Republic of Korea
| |
Collapse
|
10
|
Tian JL, Yao GD, Zhang YY, Lin B, Zhang Y, Li LZ, Huang XX, Song SJ. Pyran-2-one derivatives from Croton crassifolius as potent apoptosis inducers in HepG2 cells via p53-mediated Ras/Raf/ERK pathway. Bioorg Chem 2018; 79:355-362. [DOI: 10.1016/j.bioorg.2018.05.020] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/23/2018] [Revised: 05/17/2018] [Accepted: 05/20/2018] [Indexed: 01/22/2023]
|
11
|
Fang X, Shen F, Lechauve C, Xu P, Zhao G, Itkow J, Wu F, Hou Y, Wu X, Yu L, Xiu H, Wang M, Zhang R, Wang F, Zhang Y, Wang D, Weiss MJ, Yu D. miR-144/451 represses the LKB1/AMPK/mTOR pathway to promote red cell precursor survival during recovery from acute anemia. Haematologica 2017; 103:406-416. [PMID: 29269522 PMCID: PMC5830375 DOI: 10.3324/haematol.2017.177394] [Citation(s) in RCA: 30] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/27/2017] [Accepted: 12/20/2017] [Indexed: 12/21/2022] Open
Abstract
The microRNAs miR-144 and -451 are encoded by a bicistronic gene that is strongly induced during red blood cell formation (erythropoiesis). Ablation of the miR-144/451 gene in mice causes mild anemia under baseline conditions. Here we show that miR-144/451−/− erythroblasts exhibit increased apoptosis during recovery from acute anemia. Mechanistically, miR-144/451 depletion increases the expression of the miR-451 target mRNA Cab39, which encodes a co-factor for the serine-threonine kinase LKB1. During erythropoietic stress, miR-144/451−/− erythroblasts exhibit abnormally increased Cab39 protein, which activates LKB1 and its downstream AMPK/mTOR effector pathway. Suppression of this pathway via drugs or shRNAs enhances survival of the mutant erythroblasts. Thus, miR-144/451 facilitates recovery from acute anemia by repressing Cab39/AMPK/mTOR. Our findings suggest that miR-144/451 is a key protector of erythroblasts during pathological states associated with dramatically increased erythropoietic demand, including acute blood loss and hemolytic anemia.
Collapse
Affiliation(s)
- Xiao Fang
- Clinical Medical College of Yangzhou University, Yangzhou, China.,Jiangsu Key Laboratory of Experimental & Translational Non-Coding RNA Research, University School of Medicine, China
| | - Feiyang Shen
- Jiangsu Key Laboratory of Experimental & Translational Non-Coding RNA Research, University School of Medicine, China
| | - Christophe Lechauve
- Department of Hematology, St. Jude Children's Research Hospital, Memphis, TN, USA
| | - Peng Xu
- Department of Hematology, St. Jude Children's Research Hospital, Memphis, TN, USA
| | - Guowei Zhao
- Department of Hematology, St. Jude Children's Research Hospital, Memphis, TN, USA
| | - Jacobi Itkow
- Jiangsu Key Laboratory of Experimental & Translational Non-Coding RNA Research, University School of Medicine, China
| | - Fan Wu
- Jiangsu Key Laboratory of Experimental & Translational Non-Coding RNA Research, University School of Medicine, China
| | - Yaying Hou
- Jiangsu Key Laboratory of Experimental & Translational Non-Coding RNA Research, University School of Medicine, China
| | - Xiaohui Wu
- Jiangsu Key Laboratory of Experimental & Translational Non-Coding RNA Research, University School of Medicine, China.,Department of Pediatrics, Jingjiang People's Hospital, Yangzhou University, Jingjiang, China
| | - Lingling Yu
- Jiangsu Key Laboratory of Experimental & Translational Non-Coding RNA Research, University School of Medicine, China.,Department of Pediatrics, Jingjiang People's Hospital, Yangzhou University, Jingjiang, China
| | - Huiqing Xiu
- Jiangsu Key Laboratory of Experimental & Translational Non-Coding RNA Research, University School of Medicine, China
| | - Mengli Wang
- Jiangsu Key Laboratory of Experimental & Translational Non-Coding RNA Research, University School of Medicine, China
| | - Ruiling Zhang
- Jiangsu Key Laboratory of Experimental & Translational Non-Coding RNA Research, University School of Medicine, China
| | - Fangfang Wang
- Jiangsu Key Laboratory of Experimental & Translational Non-Coding RNA Research, University School of Medicine, China
| | - Yanqing Zhang
- Jiangsu Key Laboratory of Experimental & Translational Non-Coding RNA Research, University School of Medicine, China
| | - Daxin Wang
- Clinical Medical College of Yangzhou University, Yangzhou, China
| | - Mitchell J Weiss
- Department of Hematology, St. Jude Children's Research Hospital, Memphis, TN, USA
| | - Duonan Yu
- Jiangsu Key Laboratory of Experimental & Translational Non-Coding RNA Research, University School of Medicine, China .,Institute of Comparative Medicine, Yangzhou University, China.,Institute of Translational Medicine, Yangzhou University School of Medicine, Yangzhou, China.,Jiangsu Co-Innovation Center for Prevention and Control of Important Animal Infectious Disease and Zoonosis, Yangzhou, China
| |
Collapse
|
12
|
Gong WL, Sha C, Du G, Shan ZG, Qi ZQ, Zhou SF, Yang N, Zhao YX. Preoperative application of combination of portal venous injection of donor spleen cells and intraperitoneal injection of rapamycin prolongs the survival of cardiac allografts in mice. ASIAN PAC J TROP MED 2017. [PMID: 28647182 DOI: 10.1016/j.apjtm.2017.05.004] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/19/2022] Open
Abstract
OBJECTIVE To investigate the effects of preoperative portal venous injection of donor spleen cells (PVIDSC) and intraperitoneal injection of rapamycin in the acute rejection of cardiac allograft in mice and the underlying mechanisms. METHODS Homogenous female B6 mice and BALB/c mice were used as recipients and donors of heart transplantation. These mice were randomly divided into different groups and received PVIDSC alone, rapamycin alone, or PVIDSC and rapamycin combined therapy. In addition, the underlying mechanism was studied by measuring a number of cytokines. RESULTS Preoperative combination of PVIDSC and intraperitoneal injection of rapamycin significantly prolonged the survival of heterotopic cardiac allograft in mice, but had no effects on the survival time of cardiac allografts in mice pre-sensitized by skin grafting. Preoperative combination of PVIDSC and intraperitoneal injection of rapamycin increased the expression of IL-10 and Foxp3 and reduced the expression of INF-. Short-term preoperative administration of rapamycin promotes the expression of CD4+CD25+Foxp3+ regulator T cells. However, preoperative using alone of rapamycin, or combination of PVIDSC and rapamycin had no effects on the inhibition of proliferation of memory T cells. CONCLUSIONS Preoperative application of combination of PVIDSC and rapamycin significantly prolonged the survival time of cardiac allografts in mice but not in mice pre-sensitized by skin grafting. This may be explained by the fact that combination of PVIDSC and rapamycin inhibited the cellular immune response and induced the expression of IL-10 from Tr1 cells and CD4+CD25+FoxP3+ regulatory T cells.
Collapse
Affiliation(s)
- Wen-Lin Gong
- National Center for International Research of Biological Targeting Diagnosis and Therapy, Guangxi Key Laboratory of Biological Targeting Diagnosis and Therapy Research, Collaborative Innovation Center for Targeting Tumor Diagnosis and Therapy, Guangxi Medical University, Nanning, Guangxi, 530021, China
| | - Chuang Sha
- Department of Cardiac Surgery, Zhongshan Hospital, Xiamen University, Xiamen, China
| | - Gang Du
- National Center for International Research of Biological Targeting Diagnosis and Therapy, Guangxi Key Laboratory of Biological Targeting Diagnosis and Therapy Research, Collaborative Innovation Center for Targeting Tumor Diagnosis and Therapy, Guangxi Medical University, Nanning, Guangxi, 530021, China
| | - Zhong-Gui Shan
- Organ Transplantation Institute, Xiamen University, Xiamen, China
| | - Zhong-Quan Qi
- Organ Transplantation Institute, Xiamen University, Xiamen, China
| | - Su-Fang Zhou
- National Center for International Research of Biological Targeting Diagnosis and Therapy, Guangxi Key Laboratory of Biological Targeting Diagnosis and Therapy Research, Collaborative Innovation Center for Targeting Tumor Diagnosis and Therapy, Guangxi Medical University, Nanning, Guangxi, 530021, China
| | - Nuo Yang
- National Center for International Research of Biological Targeting Diagnosis and Therapy, Guangxi Key Laboratory of Biological Targeting Diagnosis and Therapy Research, Collaborative Innovation Center for Targeting Tumor Diagnosis and Therapy, Guangxi Medical University, Nanning, Guangxi, 530021, China; Department of Cardio-Thoracic Surgery, The First Affiliated Hospital of Guang Xi Medical University, Nanning 530021, China
| | - Yong-Xiang Zhao
- National Center for International Research of Biological Targeting Diagnosis and Therapy, Guangxi Key Laboratory of Biological Targeting Diagnosis and Therapy Research, Collaborative Innovation Center for Targeting Tumor Diagnosis and Therapy, Guangxi Medical University, Nanning, Guangxi, 530021, China; Department of Cardio-Thoracic Surgery, The First Affiliated Hospital of Guang Xi Medical University, Nanning 530021, China
| |
Collapse
|